- EsoCap successfully closes a private financing round, with investments from existing and new investors
- The new funding was facilitated by EsoCap benefitting from a unique programme implemented by the Canton of Basel-Stadt, guaranteeing subordinated loans to support technology start-ups during the Covid-19 pandemic
- The proceeds will be used for development and industrial scale-up of activities for EsoCap’s targeted application technology, enabling effective local treatment of esophageal diseases for the first time
EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, announced that it has successfully completed a financing round raising new private funding. This funding involves private placement including existing and new investors with a strong entrepreneurial background. It was facilitated by a unique subordinated loan guarantee program by the Canton of Basel-Stadt, to which EsoCap has successfully applied, which provides special support to technology start-ups during the Covid-19 pandemic.
